Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2024

Open Access 01-12-2024 | Hepatocellular Carcinoma | Review

Biological roles of SLC16A1-AS1 lncRNA and its clinical impacts in tumors

Authors: Bing Liao, Jialing Wang, Yalin Yuan, Hongliang Luo, Xi Ouyang

Published in: Cancer Cell International | Issue 1/2024

Login to get access

Abstract

Recent studies have increasingly highlighted the aberrant expression of SLC16A1-AS1 in a variety of tumor types, where it functions as either an oncogene or a tumor suppressor in the pathogenesis of different cancers. The expression levels of SLC16A1-AS1 have been found to significantly correlate with clinical features and the prognosis of cancer patients. Furthermore, SLC16A1-AS1 modulates a range of cellular functions, including proliferation, migration, and invasion, through its interactions with diverse molecules and signaling pathways. This review examines the latest evidence regarding the role of SLC16A1-AS1 in the progression of various tumors and explores its potential clinical applications as a novel prognostic and diagnostic biomarker. Our comprehensive review aims to deepen the understanding of SLC16A1-AS1’s multifaceted role in oncology, underscoring its potential as a significant biomarker and therapeutic target.
Literature
1.
2.
3.
4.
5.
Jarroux J, Morillon A, Pinskaya M. History, Discovery, and classification of lncRNAs. Adv Exp Med Biol. 2017;1008:1–46.PubMedCrossRef
6.
7.
Louro R, Smirnova AS, Verjovski-Almeida S. Long intronic noncoding RNA transcription: expression noise or expression choice? Genomics. 2009;93(4):291–8.PubMedCrossRef
8.
Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet, 2006. 15 Spec No 1: p. R17-29.
9.
10.
11.
Agnelli L, Bortoluzzi S, Pruneri G. Bioinformatic pipelines to analyze lncRNAs RNAseq Data. Methods Mol Biol. 2021;2348:55–69.PubMedCrossRef
12.
Chu C, Spitale RC, Chang HY. Technologies to probe functions and mechanisms of long noncoding RNAs. Nat Struct Mol Biol. 2015;22(1):29–35.PubMedCrossRef
13.
Signal B, Gloss BS, Dinger ME. Computational approaches for functional prediction and characterisation of long noncoding RNAs. Trends Genet. 2016;32(10):620–37.PubMedCrossRef
14.
Iwakiri J, Hamada M, Asai K. Bioinformatics tools for lncRNA research. Biochim Biophys Acta. 2016;1859(1):23–30.PubMedCrossRef
15.
16.
17.
Hu SP, et al. LncRNA HCP5 as a potential therapeutic target and prognostic biomarker for various cancers: a meta–analysis and bioinformatics analysis. Cancer Cell Int. 2021;21(1):686.PubMedPubMedCentralCrossRef
18.
Zhang L, Sun H, Chen X. Long noncoding RNAs in human reproductive processes and diseases. Mol Reprod Dev. 2024;91(1):e23728.PubMedCrossRef
19.
Tavares ESJ et al. The impact of long noncoding RNAs in tissue regeneration and senescence. Cells, 2024. 13(2).
20.
21.
22.
Rajagopal T, et al. HOTAIR LncRNA: a novel oncogenic propellant in human cancer. Clin Chim Acta. 2020;503:1–18.PubMedCrossRef
23.
Hajjari M, Salavaty A. HOTAIR: an oncogenic long non-coding RNA in different cancers. Cancer Biol Med. 2015;12(1):1–9.PubMedPubMedCentral
24.
Kuo FC, et al. LncRNA HOTAIR impairs the prognosis of papillary thyroid cancer via regulating cellular malignancy and epigenetically suppressing DLX1. Cancer Cell Int. 2022;22(1):396.PubMedPubMedCentralCrossRef
25.
26.
Hakami MA, et al. A key regulator of the Wnt/β-catenin signaling cascade in cancer progression and treatment. Pathol Res Pract. 2024;253:154957.PubMedCrossRef
27.
Wang J, et al. Long noncoding RNA HOTAIR regulates the stemness of breast cancer cells via activation of the NF-κB signaling pathway. J Biol Chem. 2022;298(12):102630.PubMedPubMedCentralCrossRef
28.
Sadeghalvad M, et al. Long non-coding RNA HOTAIR induces the PI3K/AKT/mTOR signaling pathway in breast cancer cells. Rev Assoc Med Bras (1992). 2022;68(4):456–62.PubMedCrossRef
29.
Ma Y, et al. Long non-coding RNA HOTAIR promotes cancer cell energy metabolism in pancreatic adenocarcinoma by upregulating hexokinase-2. Oncol Lett. 2019;18(3):2212–9.PubMedPubMedCentral
30.
Hu M, et al. LncRNA HOTAIR knockdown inhibits glycolysis by regulating miR-130a-3p/HIF1A in hepatocellular carcinoma under hypoxia. Biomed Pharmacother. 2020;125:109703.PubMedCrossRef
31.
Wei S, et al. Promotion of glycolysis by HOTAIR through GLUT1 upregulation via mTOR signaling. Oncol Rep. 2017;38(3):1902–8.PubMedCrossRef
32.
33.
Ma Q et al. Inducible lncRNA transgenic mice reveal continual role of HOTAIR in promoting breast cancer metastasis. Elife, 2022. 11.
34.
35.
36.
37.
Zhu JQ, et al. Sodium fluoride disrupts DNA methylation of H19 and Peg3 imprinted genes during the early development of mouse embryo. Arch Toxicol. 2014;88(2):241–8.PubMedCrossRef
38.
Ratajczak MZ. Igf2-H19, an imprinted tandem gene, is an important regulator of embryonic development, a guardian of proliferation of adult pluripotent stem cells, a regulator of longevity, and a ‘passkey’ to cancerogenesis. Folia Histochem Cytobiol. 2012;50(2):171–9.PubMedCrossRef
39.
Tabano S, et al. Epigenetic modulation of the IGF2/H19 imprinted domain in human embryonic and extra-embryonic compartments and its possible role in fetal growth restriction. Epigenetics. 2010;5(4):313–24.PubMedCrossRef
40.
Gabory A, Jammes H, Dandolo L. The H19 locus: role of an imprinted non-coding RNA in growth and development. BioEssays. 2010;32(6):473–80.PubMedCrossRef
41.
Gabory A, et al. The H19 gene: regulation and function of a non-coding RNA. Cytogenet Genome Res. 2006;113(1–4):188–93.PubMedCrossRef
42.
Viville S, Surani MA. Towards unravelling the Igf2/H19 imprinted domain. BioEssays. 1995;17(10):835–8.PubMedCrossRef
43.
44.
Yu L, et al. lncRNA-HIT promotes cell proliferation of non-small cell lung cancer by association with E2F1. Cancer Gene Ther. 2017;24(5):221–6.PubMedCrossRef
45.
Zhang J, et al. Lnc-LRRTM4 promotes proliferation, metastasis and EMT of colorectal cancer through activating LRRTM4 transcription. Cancer Cell Int. 2023;23(1):142.PubMedPubMedCentralCrossRef
46.
47.
Tao T et al. The molecular mechanisms of LncRNA-correlated PKM2 in cancer metabolism. Biosci Rep, 2019. 39(11).
48.
49.
Chen D, et al. LncRNA NEAT1 suppresses cellular senescence in hepatocellular carcinoma via KIF11-dependent repression of CDKN2A. Clin Transl Med. 2023;13(9):e1418.PubMedPubMedCentralCrossRef
50.
51.
Wang PS, Wang Z, Yang C. Dysregulations of long non-coding RNAs - the emerging lnc in environmental carcinogenesis. Semin Cancer Biol. 2021;76:163–72.PubMedPubMedCentralCrossRef
52.
Nemeth K et al. Non-coding RNAs in disease: from mechanisms to therapeutics. Nat Rev Genet, 2023.
53.
54.
55.
Ghasemian M, et al. Long non-coding RNA MIR4435-2HG: a key molecule in progression of cancer and non-cancerous disorders. Cancer Cell Int. 2022;22(1):215.PubMedPubMedCentralCrossRef
56.
Ma Y, et al. LncRNA: an important Regulator of Atherosclerosis. Curr Med Chem. 2023;30(38):4340–54.PubMedCrossRef
57.
Mao Y, Yue H, Dong F. LncRNA CDKN2B-AS1 in atherosclerosis: friend or foe? Int J Cardiol. 2021;343:106.PubMedCrossRef
58.
Bian W, et al. Downregulation of LncRNA NORAD promotes Ox-LDL-induced vascular endothelial cell injury and atherosclerosis. Aging. 2020;12(7):6385–400.PubMedPubMedCentralCrossRef
59.
Li Y, et al. Targeting lncRNA NEAT1 hampers Alzheimer’s Disease Progression. Neuroscience. 2023;529:88–98.PubMedCrossRef
60.
61.
Maoz R, Garfinkel BP, Soreq H. Alzheimer’s Disease and ncRNAs. Adv Exp Med Biol. 2017;978:337–61.PubMedCrossRef
62.
Lei HT, et al. LncRNA-mediated cell autophagy: an emerging field in bone destruction in rheumatoid arthritis. Biomed Pharmacother. 2023;168:115716.PubMedCrossRef
63.
Yang J, et al. The role of non-coding RNAs (miRNA and lncRNA) in the clinical management of rheumatoid arthritis. Pharmacol Res. 2022;186:106549.PubMedCrossRef
64.
Li Z et al. Long non-coding RNAs in rheumatoid arthritis. Cell Prolif, 2018. 51(1).
65.
66.
67.
68.
Ouyang J, et al. Long non-coding RNAs are involved in alternative splicing and promote cancer progression. Br J Cancer. 2022;126(8):1113–24.PubMedCrossRef
69.
Najafi S, et al. Long non-coding RNAs (lncRNAs); roles in tumorigenesis and potentials as biomarkers in cancer diagnosis. Exp Cell Res. 2022;418(2):113294.PubMedCrossRef
70.
71.
Chen Y, et al. Long non-coding RNAs: from disease code to drug role. Acta Pharm Sin B. 2021;11(2):340–54.PubMedCrossRef
72.
Pierce JB, et al. Long noncoding RNAs as therapeutic targets. Adv Exp Med Biol. 2022;1363:161–75.PubMedCrossRef
73.
Nemeth K, et al. Non-coding RNAs in disease: from mechanisms to therapeutics. Nat Rev Genet. 2024;25(3):211–32.PubMedCrossRef
74.
Xing H, Meng L-h. CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment. Acta Pharmacol Sin. 2020;41(5):583–7.PubMedCrossRef
75.
Srinivas T, Siqueira E, Guil S. Techniques for investigating lncRNA transcript functions in neurodevelopment. Mol Psychiatry, 2023.
76.
Mahato RK, et al. Targeting long non-coding RNAs in cancer therapy using CRISPR-Cas9 technology: a novel paradigm for precision oncology. J Biotechnol. 2024;379:98–119.PubMedCrossRef
77.
M SZ, Hartford CCR, Lal A. Interrogating lncRNA functions via CRISPR/Cas systems. RNA Biol. 2021;18(12):2097–106.CrossRef
78.
79.
Mattick JS, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24(6):430–47.PubMedCrossRef
80.
81.
Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA Biol. 2013;10(6):925–33.PubMedCrossRef
82.
Yousefi H, et al. Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance. Oncogene. 2020;39(5):953–74.PubMedCrossRef
83.
Sebastian-delaCruz M et al. The role of lncRNAs in Gene expression regulation through mRNA stabilization. Noncoding RNA, 2021. 7(1).
84.
Statello L, et al. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96–118.PubMedCrossRef
85.
86.
87.
Pisignano G, Ladomery M. Post-transcriptional regulation through long non-coding RNAs (lncRNAs). Noncoding RNA, 2021. 7(2).
88.
89.
90.
91.
92.
Rehman SU, et al. Recent insights into the functions and mechanisms of antisense RNA: emerging applications in cancer therapy and precision medicine. Front Chem. 2023;11:1335330.PubMedCrossRef
93.
Jin Z, et al. MicroRNA-1269 is downregulated in glioblastoma and its maturation is regulated by long non-coding RNA SLC16A1 antisense RNA 1. Bioengineered. 2022;13(5):12749–59.PubMedPubMedCentralCrossRef
94.
Long Y, et al. LncRNA SLC16A1-AS1 is upregulated in Glioblastoma and promotes Cancer Cell Proliferation by regulating miR-149 methylation. Cancer Manag Res. 2021;13:1215–23.PubMedPubMedCentralCrossRef
95.
Li T, Wang D, Yang S. Analysis of the subcellular location of lncRNA SLC16A1-AS1 and its interaction with premature mir-5088-5p in oral squamous cell carcinoma. Odontology. 2023;111(1):41–8.PubMedCrossRef
96.
Feng H, et al. Long non-coding RNA SLC16A1-AS1: its multiple tumorigenesis features and regulatory role in cell cycle in oral squamous cell carcinoma. Cell Cycle. 2020;19(13):1641–53.PubMedPubMedCentralCrossRef
97.
Tian J, Hu D. LncRNA SLC16A1-AS1 is upregulated in hepatocellular carcinoma and predicts poor survival. Clin Res Hepatol Gastroenterol. 2021;45(2):101490.PubMedCrossRef
98.
Pei S, et al. SLC16A1-AS1 enhances radiosensitivity and represses cell proliferation and invasion by regulating the miR-301b-3p/CHD5 axis in hepatocellular carcinoma. Environ Sci Pollut Res Int. 2020;27(34):42778–90.PubMedCrossRef
99.
Duan C. LncRNA SLC16A1-AS1 contributes to the progression of hepatocellular carcinoma cells by modulating miR-411/MITD1 axis. J Clin Lab Anal. 2022;36(4):e24344.PubMedPubMedCentralCrossRef
100.
Song M, et al. Large-scale analyses identify a cluster of novel long noncoding RNAs as potential competitive endogenous RNAs in progression of hepatocellular carcinoma. Aging. 2019;11(22):10422–53.PubMedPubMedCentralCrossRef
101.
Li YZ, et al. Silencing lncRNA SLC16A1-AS1 Induced Ferroptosis in Renal Cell Carcinoma through miR-143-3p/SLC7A11 signaling. Technol Cancer Res Treat. 2022;21:15330338221077803.PubMedPubMedCentralCrossRef
102.
Logotheti S, et al. LncRNA-SLC16A1-AS1 induces metabolic reprogramming during bladder Cancer progression as target and co-activator of E2F1. Theranostics. 2020;10(21):9620–43.PubMedPubMedCentralCrossRef
103.
Zhang H, et al. LncRNA SLC16A1-AS1 suppresses cell proliferation in cervical squamous cell carcinoma (CSCC) through the miR-194/SOCS2 Axis. Cancer Manag Res. 2021;13:1299–306.PubMedPubMedCentralCrossRef
104.
Zhao X, et al. MiR-526b targets lncRNA SLC16A1-AS1 to suppress cell proliferation in triple-negative breast cancer. J Biochem Mol Toxicol. 2023;37(3):e23247.PubMedCrossRef
105.
Jiang B, Xia J, Zhou X. Overexpression of lncRNA SLC16A1-AS1 suppresses the growth and metastasis of breast Cancer via the miR-552-5p/WIF1 signaling pathway. Front Oncol. 2022;12:712475.PubMedPubMedCentralCrossRef
106.
Jiang B, et al. LncRNA SLC16A1-AS1 regulates the miR-182/PDCD4 axis and inhibits the triple-negative breast cancer cell cycle. Immunopharmacol Immunotoxicol. 2022;44(4):534–40.PubMedCrossRef
107.
Rothzerg E et al. Upregulation of 15 antisense long non-coding RNAs in Osteosarcoma. Genes (Basel), 2021. 12(8).
108.
Liu HY, et al. lncRNA SLC16A1-AS1 as a novel prognostic biomarker in non-small cell lung cancer. J Investig Med. 2020;68(1):52–9.PubMedCrossRef
109.
110.
111.
112.
113.
Hirschhorn T, Stockwell BR. The development of the concept of ferroptosis. Free Radic Biol Med. 2019;133:130–43.PubMedCrossRef
114.
Lee J, Roh JL. SLC7A11 as a gateway of metabolic perturbation and ferroptosis vulnerability in Cancer. Antioxid (Basel), 2022. 11(12).
115.
Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12(8):599–620.PubMedCrossRef
116.
Lin W, et al. SLC7A11/xCT in cancer: biological functions and therapeutic implications. Am J Cancer Res. 2020;10(10):3106–26.PubMedPubMedCentral
117.
Denechaud PD, Fajas L, Giralt A. E2F1, a Novel Regulator of Metabolism. Front Endocrinol (Lausanne). 2017;8:311.PubMedCrossRef
118.
119.
Zu ML, et al. Gypenoside LI arrests the cell cycle of breast cancer in G0/G1 phase by down-regulating E2F1. J Ethnopharmacol. 2021;273:114017.PubMedCrossRef
120.
Li P, et al. E2F transcription factor 1 is involved in the phenotypic modulation of esophageal squamous cell carcinoma cells via microRNA-375. Bioengineered. 2021;12(2):10047–62.PubMedPubMedCentralCrossRef
121.
Shen C, et al. [Advancement of E2F1 in Common Tumors]. Zhongguo Fei Ai Za Zhi. 2020;23(10):921–6.PubMed
122.
Ohshima K, Morii E. Metabolic reprogramming of Cancer cells during Tumor Progression and Metastasis. Metabolites, 2021. 11(1).
123.
Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669–80.PubMedCrossRef
124.
Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science, 2020. 368(6487).
125.
126.
Schiliro C, Firestein BL. Mechanisms of metabolic reprogramming in Cancer cells supporting enhanced growth and proliferation. Cells, 2021. 10(5).
127.
DeBerardinis RJ, et al. The Biology of Cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabol. 2008;7(1):11–20.CrossRef
128.
Wang B, et al. MiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway. Cell Cycle. 2015;14(7):1046–58.PubMedPubMedCentralCrossRef
129.
Huang P, et al. Genome-wide association studies identify miRNA-194 as a prognostic biomarker for gastrointestinal cancer by targeting ATP6V1F, PPP1R14B, BTF3L4 and SLC7A5. Front Oncol. 2022;12:1025594.PubMedPubMedCentralCrossRef
130.
Yin W, Shi L, Mao Y. MiR-194 regulates nasopharyngeal carcinoma progression by modulating MAP3K3 expression. FEBS Open Bio. 2019;9(1):43–52.PubMedCrossRef
131.
Vitali C, et al. SOCS2 controls proliferation and stemness of Hematopoietic Cells under stress conditions and its Deregulation Marks unfavorable Acute Leukemias. Cancer Res. 2015;75(11):2387–99.PubMedCrossRef
132.
Jian F, et al. The long-noncoding RNA SOCS2-AS1 suppresses endometrial cancer progression by regulating AURKA degradation. Cell Death Dis. 2021;12(4):351.PubMedPubMedCentralCrossRef
133.
Cabrera-Galván JJ, et al. SOCS2 protects against chemical-induced hepatocellular carcinoma progression by modulating inflammation and cell proliferation in the liver. Biomed Pharmacother. 2023;157:114060.PubMedCrossRef
134.
Masuzaki R et al. Suppressors of Cytokine Signaling and Hepatocellular Carcinoma. Cancers (Basel), 2022. 14(10).
135.
Wan W, et al. Isoprenylcysteine carboxyl methyltransferase is critical for glioblastoma growth and survival by activating Ras/Raf/Mek/Erk. Cancer Chemother Pharmacol. 2022;89(3):401–11.PubMedCrossRef
136.
Steelman LS, et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia. 2011;25(7):1080–94.PubMedCrossRef
137.
McCubrey JA, et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia. 2008;22(4):708–22.PubMedCrossRef
138.
Ufuk A et al. Monocarboxylate transporters are involved in Extracellular Matrix Remodelling in Pancreatic Ductal Adenocarcinoma. Cancers (Basel), 2022. 14(5).
139.
140.
Poursheikhani A, et al. Integration analysis of long non-coding RNA (lncRNA) role in tumorigenesis of colon adenocarcinoma. BMC Med Genomics. 2020;13(1):108.PubMedPubMedCentralCrossRef
141.
Gong M, et al. Upregulation of BMP1 through ncRNAs correlates with adverse outcomes and immune infiltration in clear cell renal cell carcinoma. Eur J Med Res. 2023;28(1):440.PubMedPubMedCentralCrossRef
142.
143.
Zhou X, et al. m6A-related long noncoding RNAs predict prognosis and indicate therapeutic response in endometrial carcinoma. J Clin Lab Anal. 2023;37(1):e24813.PubMedCrossRef
144.
Tang Z, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–w560.PubMedPubMedCentralCrossRef
145.
Liu S, et al. COLGALT1 is a potential biomarker for predicting prognosis and immune responses for kidney renal clear cell carcinoma and its mechanisms of ceRNA networks. Eur J Med Res. 2022;27(1):122.PubMedPubMedCentralCrossRef
146.
147.
Xiong Y, et al. The VIM-AS1/miR-655/ZEB1 axis modulates bladder cancer cell metastasis by regulating epithelial-mesenchymal transition. Cancer Cell Int. 2021;21(1):233.PubMedPubMedCentralCrossRef
148.
149.
Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 2019;19(7):405–14.PubMedCrossRef
150.
Roh J et al. The involvement of long non-coding RNAs in glutamine-metabolic reprogramming and therapeutic resistance in Cancer. Int J Mol Sci, 2022. 23(23).
151.
Weber DG, et al. Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer. BMC Res Notes. 2013;6:518.PubMedPubMedCentralCrossRef
152.
Ren S, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer. 2013;49(13):2949–59.PubMedCrossRef
153.
Mohyeldeen M, et al. Serum expression and diagnostic potential of long non-coding RNAs NEAT1 and TUG1 in viral hepatitis C and viral hepatitis C-associated hepatocellular carcinoma. Clin Biochem. 2020;84:38–44.PubMedCrossRef
154.
Yin Q, et al. Elevated serum lncRNA TUG1 levels are a potential diagnostic biomarker of multiple myeloma. Exp Hematol. 2019;79:47–55e2.PubMedCrossRef
Metadata
Title
Biological roles of SLC16A1-AS1 lncRNA and its clinical impacts in tumors
Authors
Bing Liao
Jialing Wang
Yalin Yuan
Hongliang Luo
Xi Ouyang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2024
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-024-03285-6

Other articles of this Issue 1/2024

Cancer Cell International 1/2024 Go to the issue

Research

Deciphering the prognostic features of bladder cancer through gemcitabine resistance and immune-related gene analysis and identifying potential small molecular drug PIK-75

Research

PHF6 loss reduces leukemia stem cell activity in an acute myeloid leukemia mouse model

Research

Microglia-mediated drug substance transfer promotes chemoresistance in brain tumors: insights from an in vitro co-culture model using GCV/Tk prodrug system

Research

PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma

Research

The therapeutic effect of a novel GAPDH inhibitor in mouse model of breast cancer and efficacy monitoring by molecular imaging

Research

LncRNA CRNDE promotes hepatoma cell proliferation by regulating the metabolic reprogramming of M2 macrophages via ERK pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits